Vascular Endothelial Growth Factor D
"Vascular Endothelial Growth Factor D" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A vascular endothelial growth factor that specifically binds to VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 and VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3. In addition to being an angiogenic factor it can act on LYMPHATIC VESSELS to stimulate LYMPHANGIOGENESIS. It is similar in structure to VASCULAR ENDOTHELIAL GROWTH FACTOR C in that they both contain N- and C-terminal extensions that were not found in other VEGF family members.
| Descriptor ID |
D042643
|
| MeSH Number(s) |
D12.644.276.100.800.500 D12.776.467.100.800.500 D23.529.100.800.500
|
| Concept/Terms |
Vascular Endothelial Growth Factor D- Vascular Endothelial Growth Factor D
- VEGF-D
- Vascular Endothelial Growth Factor-D
- c-fos-Induced Growth Factor
- c fos Induced Growth Factor
- FIGF Protein
|
Below are MeSH descriptors whose meaning is more general than "Vascular Endothelial Growth Factor D".
Below are MeSH descriptors whose meaning is more specific than "Vascular Endothelial Growth Factor D".
This graph shows the total number of publications written about "Vascular Endothelial Growth Factor D" by people in this website by year, and whether "Vascular Endothelial Growth Factor D" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vascular Endothelial Growth Factor D" by people in Profiles.
-
Cohort study on the differential expression of inflammatory and angiogenic factors in thrombi, cerebral and peripheral plasma following acute large vessel occlusion stroke. J Cereb Blood Flow Metab. 2022 10; 42(10):1827-1839.
-
Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. Clin Transl Med. 2021 07; 11(7):e491.
-
Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study. Eur J Cancer. 2020 03; 127:150-157.
-
Aberrant SYK Kinase Signaling Is Essential for Tumorigenesis Induced by TSC2 Inactivation. Cancer Res. 2017 03 15; 77(6):1492-1502.
-
Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis: Results of a Phase I Clinical Trial. Chest. 2017 06; 151(6):1302-1310.
-
Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study. Eur Respir J. 2015 Sep; 46(3):783-94.
-
Transforming growth factor-?1 downregulates vascular endothelial growth factor-D expression in human lung fibroblasts via the Jun NH2-terminal kinase signaling pathway. Mol Med. 2014 Mar 20; 20:120-34.
-
Vascular endothelial growth factors C and D induces proliferation of lymphangioleiomyomatosis cells through autocrine crosstalk with endothelium. Am J Pathol. 2009 Oct; 175(4):1410-20.
-
DNA demethylation of vascular endothelial growth factor-C is associated with gene expression and its possible involvement of lymphangiogenesis in gastric cancer. Int J Cancer. 2007 Apr 15; 120(8):1689-95.
-
Inhibition of vascular endothelial growth factor (VEGF)-A causes a paradoxical increase in tumor blood flow and up-regulation of VEGF-D. Clin Cancer Res. 2006 Mar 01; 12(5):1525-32.